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Cardiomyocyte Overexpression of Neuronal Nitric Oxide
Synthase Delays Transition Toward Heart Failure in
Response to Pressure Overload by Preserving
Calcium Cycling
Xavier Loyer, PhD*; Ana Maria Gómez, PhD*; Paul Milliez, MD, PhD;
Maria Fernandez-Velasco, PhD; Peter Vangheluwe, PhD; Laurent Vinet, BSc;
Dominique Charue, BSc; Emilie Vaudin, BSc; Wei Zhang, BSc; Yannis Sainte-Marie, PhD;
Estelle Robidel, BSc; Isabelle Marty, PhD; Bernd Mayer, PhD; Frédéric Jaisser, MD, PhD;
Jean-Jacques Mercadier, MD, PhD; Sylvain Richard, PhD; Ajay M. Shah, MD, FRCP;
Jean-Pierre Bénitah, PhD; Jane-Lise Samuel, MD, PhD; Christophe Heymes, PhD
Background—Defects in cardiomyocyte Ca2 cycling are a signature feature of heart failure (HF) that occurs in response
to sustained hemodynamic overload, and they largely account for contractile dysfunction. Neuronal nitric oxide synthase
(NOS1) influences myocyte excitation-contraction coupling through modulation of Ca2 cycling, but the potential
relevance of this in HF is unknown.
Methods and Results—We generated a transgenic mouse with conditional, cardiomyocyte-specific NOS1 overexpression
(double-transgenic [DT]) and studied cardiac remodeling, myocardial Ca2 handling, and contractility in DT and control
mice subjected to transverse aortic constriction (TAC). After TAC, control mice developed eccentric hypertrophy with
evolution toward HF as revealed by a significantly reduced fractional shortening. In contrast, DT mice developed a
greater increase in wall thickness (P0.0001 versus controlTAC) and less left ventricular dilatation than
controlTAC mice (P0.0001 for both end-systolic and end-diastolic dimensions). Thus, DT mice displayed
concentric hypertrophy with fully preserved fractional shortening (43.70.6% versus 30.32.6% in controlTAC
mice, P0.05). Isolated cardiomyocytes from DTTAC mice had greater shortening, intracellular Ca2 transients, and
sarcoplasmic reticulum Ca2 load (P0.05 versus controlTAC for all parameters). These effects could be explained,
at least in part, through modulation of phospholamban phosphorylation status.
Conclusions—Cardiomyocyte NOS1 may be a useful target against cardiac deterioration during chronic pressure-
overload–induced HF through modulation of calcium cycling. (Circulation. 2008;117:3187-3198.)
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A primary event in the pathogenesis of heart failure (HF)induced by hemodynamic overload is cardiomyocyte
hypertrophy. During chronic pressure overload, hypertrophy
progresses to a decompensated phase with cardiac dilation
and contractile impairment.1–4 The prevention of this deteri-
oration is a major therapeutic goal. Recent studies suggest
that a critical factor causing cardiac decompensation after
pressure overload may be the failure to preserve myocardial
inotropy.
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Defects in cardiomyocyte sarcoplasmic reticulum (SR)
Ca2 cycling are a signature feature of experimental and
human HF that largely accounts for contractile dysfunction.4,5
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A prominent abnormality is a decrease in SR Ca2 reentry,
which is predominantly governed by the activity of SR
calcium ATPase2 (SERCA2a) and controlled by its inhibitory
protein, phospholamban (PLB).6,7 Increasing SR Ca2 re-
uptake by stimulating SERCA2a has been proposed as an
approach to improving cardiomyocyte function in the failing
myocardium.8,9
Previous studies using mice with global deficiency of
neuronal nitric oxide synthase (NOS1 knockout mice,
NOS1/) suggested that NOS1 influences several aspects of
myocardial excitation-contraction coupling, including sar-
colemmal Ca2 influx through L-type channels, SR Ca2
content, and SR Ca2 release. NOS1 is located at dyadic
sarcolemmal-SR junctions, where it is in close proximity to
both L-type channels and SR Ca2 release channels (ryano-
dine receptors [RyR2]),10 and it has been suggested that it
may act physiologically to optimize excitation-contraction
coupling.11–14 However, the impact of NOS1 on myocardial
contractility and Ca2 cycling remains controversial, and the
potential relevance of this mechanism in HF is unknown.
Nevertheless, it is intriguing that NOS1 expression and
activity are significantly increased in the hypertrophic15 or
failing16,17 rat myocardium and in failing human hearts.18
Moreover, NOS1 gene deletion is associated with more
severe cardiac remodeling and functional deterioration in
murine models of myocardial infarction, which suggests that
cardiomyocyte NOS1 may play an active role in the myocar-
dial stress response.19,20 In the present study, we tested the
hypothesis that NOS1 overexpression within cardiomyocytes
may be beneficial during chronic hemodynamic overload by
favorably modulating Ca2 cycling and myocardial
contractility.
Methods
Generation of Transgenic Mice
The human NOS1 (hNOS1, -isoform) coding sequence was used to
generate the hNOS1 conditional model. The fragment of hNOS1 that
included the full-length coding sequence was blunt-ended and
inserted into the EcoRV site located between the tetO promoter and
the rabbit -globin polyadenylation sequence of the bidirectional
tet-inducible pBI4 vector, which resulted in the tetO-hNOS1 con-
struct. Double-transgenic (DT) mice were obtained by crossing the
tetO-hNOS1 mice with the -MHCtTA transactivator mouse strain
(kindly provided by G.I. Fishman, New York University School of
Medicine, New York), which allows conditional, cardiac-specific
transgene expression as early as embryonic day 9.5 (E9.5). In all
experiments, male and age-matched nontransgenic littermates were
used for comparison with DT mice. The present study was conducted
in accordance with institutional guidelines and those formulated by
the European Community for experimental animal use
(L358-86/609/EEC).
Determination of NOS Activity
Ca2-dependent activity was determined from myocardial homoge-
nates by [3H]-L-arginine to [3H]-L-citrulline conversion, according to
the manufacturer’s instructions (nitric oxide assay kit, Calbiochem,
San Diego, Calif). Assays for specific NOS1 activity were performed
in the presence of the preferential NOS1 inhibitor, vinyl-L-N-5-(1-
imino-3-butenyl)-L-ornithine (L-VNIO; 0.1 mol/L; Axxora LLC,
San Diego, Calif).
Immunoblots of Cardiac Lysates
Immunoblots and coimmunoprecipitations assays were performed on
homogenates of ventricular tissue with anti-NOS1, anti-NOS3,
anti-VEGF (vascular endothelial growth factor), anti-SERCA2a
from Santa Cruz Biotechnology Inc (Santa Cruz, Calif); anti-VEGF
receptor 2 (Flk-1) from US Biological (Marblehead, Mass); anti-
phospho-PLB (Ser16 and Thr17) from Badrilla Ltd (Leeds, United
Kingdom); anti-phosphorylated glycogen synthase kinase (GSK)-3
and anti-GSK-3 from Cell Signaling (Danvers, Mass); anti-
GAPDH from Chemicon International (Temecula, Calif); anti-PLB,
anti-NOS1, and anti-RyR2 from Affinity Bioreagents (Neshanic
Station, NJ); and anti-calmodulin from Zymed Laboratories, Inc
(South San Francisco, Calif).
Left Ventricular Pressure Overload
and Echocardiography
Transverse aortic constriction (TAC) surgery and echocardiography
were performed with protocols blinded with respect to genotype.
Reverse-Transcriptase Polymerase Chain Reaction
Total RNA extraction and a reverse-transcription reaction were
performed, as described previously. Details of primer sequences are
listed in the online-only Data Supplement.
Ca2 Imaging and Cellular Electrophysiology
Single ventricular myocytes were prepared by enzymatic dissocia-
tion. Myocytes were loaded with the cell-permeant Ca2 fluorescent
dye fluo-3 AM. Confocal images were acquired in the line-scan
mode. L-type Ca2 current was measured with the whole-cell
patch-clamp technique.
Statistical Analysis
A detailed Methods section can be found in the online-only Data
Supplement. Results are expressed as meanSEM. One-way
ANOVA followed by a post hoc Bonferroni t test was used in Figure
1. The interaction between genotype and the response to pressure
overload was tested with a 2-way ANOVA followed by a post hoc
Dunnett’s test (Figures 2 through 8). Results were considered
significant if P0.05.
The authors had full access to the data and take full responsibility
for its integrity. All authors have read and agree to the manuscript as
written.
Results
Conditional Expression of Human NOS1 in the
Heart of Transgenic Mice
Reverse-transcription polymerase chain reaction, Western
blot analysis, and immunostaining confirmed that human
NOS1 (hNOS1) was expressed only in hearts from DT mice
and not in doxycycline-treated DT mice, which shows that the
system is not leaky and that hNOS1 is not expressed in
monotransgenic tetO-hNOS1 (Figure 1A through 1E). Car-
diac extracts from DT mice exhibited markedly greater NOS1
activity than tetO-hNOS1 and doxycycline-treated mice.
NOS1 overexpression was not associated with any change in
NOS3 protein (Figure 1F). The tetO-hNOS1, wild-type lit-
termates, and doxycycline-treated DT mice were phenotypi-
cally similar, had similar survival rates and echocardiograph-
ic parameters, and were used interchangeably as controls for
the following experiments (control; not shown). Basal cardiac
morphology was unaltered, but cardiac function assessed by
echocardiographic fractional shortening was increased signif-
icantly in DT compared with control mice (43.61.2%
versus 40.60.3%, P0.05).
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Effect of TAC on NOS1 Expression, Activity,
and Localization
After TAC, both cardiac endogenous NOS1 and exogenous
transgenic hNOS1 expression increased significantly, as de-
scribed previously (Figure 2A).21 TAC induced a 3-fold
increase in specific NOS1 activity in both groups (22.36.9
in control versus 72.114.6 fmol · g protein1 · min1 in
controlTAC (CtrlTAC) mice, P0.01; 117.311.1 in
DT versus 36332.9 fmol · g protein1 · min1 in DTTAC
mice, P0.01; n5 to 7 per group). In DTTAC mice
treated for 3 weeks with doxycycline before surgery, cardiac
NOS1 activity returned to values observed in CtrlTAC
mice (81.111.1 fmol · g protein1 · min1, PNS versus
CtrlTAC). To more specifically assess the subcellular
localization of both endogenous NOS1 and transgenic
hNOS1, we studied protein-protein interactions between
NOS1 and caveolin-3 (Cav-3) or RyR2. Both antibodies
coprecipitated NOS1 in myocardial extracts from control and
DT mice (Figure 2B), but the NOS1 signal intensity was
increased significantly in DT hearts (0.3350.048 arbitrary
units [AU] in wild-type versus 0.5230.37 AU in DT for
NOS1/Cav-3 complexes, P0.05; 0.01930.012 AU in con-
trol versus 0.4970.036 AU in DT for RyR2/NOS1 com-
plexes, P0.05; n3 to 5 per group). In contrast to the HF
situation during which NOS1 is translocated to caveolae
through interactions with Cav-3, pressure overload did not
alter the amount of the NOS1/Cav-3 complex.21 Immunopre-
cipitation with anti-RyR2 revealed a decreased immunoreac-
tivity with endogenous NOS1 in CtrlTAC (0.1930.012
AU in wild-type versus 0.130.08 AU in CtrlTAC,
P0.05). In contrast, the amount of RyR2/NOS1 complexes
was maintained in DTTAC mice.
Cardiomyocyte NOS1 Overexpression Protects
Against Maladaptive Hypertrophy After TAC
Six weeks after TAC, control mice showed a 50% increase in
heart weight–to–tibia length ratio compared with sham controls;
however, DT mice displayed a further 20% increase in cardiac
hypertrophy compared with CtrlTAC mice, an effect not seen
in doxycycline-treated DTTAC mice. A similar difference in
cardiomyocyte cross-sectional areas was also confirmed by
morphometric analysis of LV sections (Figure 2D).
Transthoracic echocardiography demonstrated that control
mice subjected to TAC developed a modest increase in wall
thickness and significant chamber enlargement, characterized
by increased LV end-diastolic and end-systolic dimensions
(Figure 3). The eccentric hypertrophy and unfavorable geo-
metric adaptation to sustained pressure overload were accom-
Figure 1. Conditional cardiac hNOS1
overexpression. Cardiac hNOS1 mRNA
(A) and protein (B), as determined by
reverse-transcription polymerase chain
reaction and immunoblot, were expressed
in heart of 2-month-old DT mice only
(1 mouse per lane). No expression was
detectable in monotransgenic littermate
(tetO-hNOS1), which indicates that con-
trol of the transgene is not leaky. Expres-
sion of hNOS1 in DT mice was prevented
by doxycycline treatment (DOX, 1 g/kg)
for 3 weeks. C, hNOS1 expression, as
determined by reverse-transcription poly-
merase chain reaction, is restricted to
heart of DT mice. Expression of the trans-
gene is absent in kidney, lung, muscle,
and brain. D, Representative dual labeling
of LV sections for vinculin (red) and
hNOS1 (green) in tetO-hNOS1, DT, and
DOX-treated mice, demonstrating
increased abundance of the transgene in
numerous cardiomyocytes of DT mice
only. Inset represents longitudinal section
of cardiomyocytes. E, NOS1 activities
based on L-citrulline formation. NOS1
activity was determined with the NOS1
inhibitor L-VNIO. Note the 5-fold increase
in NOS1 activity in DT only, this effect
being reversed after administration of
DOX for 3 weeks. F, Immunoblots dem-
onstrating that cardiomyocyte overex-
pression of NOS1 did not induce any
change in NOS3 protein expression.
*P0.05 vs basal. Ctrl indicates control.
Loyer et al NOS1 and Ca2 Cycling in Cardiac Hypertrophy 3189
 at BIBLIOTHEQUE INTERUNIVERSITAIR on January 14, 2010 circ.ahajournals.orgDownloaded from 
panied by a significantly decreased fractional shortening
compared with control sham-operated mice (30.32.6%
versus 40.60.3%, P0.001). In contrast, DT mice devel-
oped a greater increase in wall thickness (P0.01 versus
CtrlTAC) but had reduced LV dimensions compared with
CtrlTAC mice (P0.01 for both LV end-diastolic and
end-systolic dimensions). Thus, DT mice displayed concen-
tric hypertrophy and fully preserved fractional shortening
after TAC. Conversely, doxycycline-treated mice subjected
to TAC displayed cardiac remodeling and function similar to
the CtrlTAC group. Taken together, these data indicate that
NOS1 overexpression maintains concentric hypertrophic re-
modeling and prevents the onset of HF.
In addition to biomechanical stress, several neurohu-
moral factors are also potent hypertrophic agents. To
investigate whether NOS1 affects hypertrophy in the
absence of hemodynamic overload, mice were treated
chronically (14 days) with the -adrenergic agonist iso-
proterenol (30 mg · kg1 · d1). No difference was observed
in blood pressure between groups. Isoproterenol induced
similar hypertrophy in control and DT mice, as assessed by
heart weight–to–tibia length ratio and cardiomyocyte
cross-sectional area (Data Supplement Figure I).
Markers of Adaptive Hypertrophy in DT Mice
After TAC
The concentric LV remodeling and preserved contractile func-
tion in DT mice suggested that cardiomyocyte NOS1 overex-
pression could be associated with an enhanced adaptive hyper-
trophic program. In contrast to adaptive hypertrophy,
Figure 2. A, Western blot and densito-
metric data reflecting endogenous NOS1
and exogenous human NOS1 (hNOS1)
protein expression in control (Ctrl) and DT
LV homogenates in response to pressure
overload. B, Association between endog-
enous NOS1 and hNOS with either Cav-3
or RyR2. LV lysates or crude particulate
preparations were immunoprecipitated
with anti-NOS1 polyclonal antibody or
anti-RyR2 polyclonal antibody. Immuno-
precipitates (IPs) were immunoblotted (IB)
for Cav-3 or NOS1. C, Mean data for
heart weight–to–tibia length ratio (n5 per
group). D, Representative immunostaining
of heart sections with anti-Cav-3 and
summary quantification of cardiomyocyte
cross-sectional area (n6 to 8 per group).
*P0.05 vs basal; †P0.05 vs CtrlTAC;
#P0.05 vs DTTAC; $P0.05 vs DT;
&P0.05 vs Ctrl.
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pathological hypertrophy is consistently associated with the
reexpression of fetal genes. As expected, TAC robustly in-
creased mRNA levels of atrial natriuretic factor, brain natriuretic
peptide, -myosin heavy chain, and skeletal muscle (SK)-actin
in control mice (Figure 4A). In marked contrast, none of these
genes were upregulated in DT mice. Interstitial cardiac fibrosis
assessed by Sirius red staining revealed a similar increase in
control and DT mice (Figure 4B).
Pressure-overload–induced maladaptive cardiac hypertro-
phy is also associated with a reduction in capillary density. As
expected, TAC significantly decreased capillary density in
control mice (Figure 5A). However, cardiomyocyte NOS1
overexpression prevented the TAC-induced decrease in cap-
illary density, with DTTAC hearts displaying a normal
capillary density compared with CtrlTAC hearts despite
their greater extent of hypertrophy. Similar results were
obtained when we studied the capillary-to-cardiomyocyte
ratio (data not shown). We next investigated a major angio-
genic growth factor/receptor system, VEGF/VEGF receptor 2
(Flk-1). TAC was associated with a significant increase in
VEGF protein expression in control mice, but Flk-1
protein expression was decreased significantly, which
could explain the observed decrease in capillary density
(Figure 5B). In contrast, DT mice displayed a further
significant increase in VEGF protein expression compared
with CtrlTAC mice, together with an increased level of
Flk-1 receptor (Figure 5B).
Effects of NOS1 Overexpression on Myocyte
Contractility, Ca2 Cycling, and Ca2
Handling Proteins
To examine whether NOS1 may be protective through mod-
ulation of Ca2 cycling, we next examined intracellular Ca2
and contraction in isolated cardiomyocytes from control and
DT mice subjected to TAC or sham surgery. Figure 6A shows
confocal line-scan images of steady state [Ca2]i transients.
Peak amplitude of [Ca2]i transient was greater in DT
myocytes than in control myocytes (by 26%, P0.005) in the
sham groups and was associated with increased cell shorten-
ing (by 43%, P0.05; Figure 6B). The time to peak of the
Ca2 transients was significantly lower in DT myocytes than
in control (20.61.1 versus 27.72.0 ms, P0.05). The
[Ca2]i transient also declined more rapidly in DT myocytes
than in control, but SR Ca2 content estimated after rapid
caffeine application was similar in the 2 groups. We thus
considered that the increased Ca2 transients in DT myocytes
despite a similar SR Ca2 content might result from modula-
tion of L-type Ca2 current (ICaL), the trigger of SR Ca2
release. Indeed, the density of ICaL tested at different potentials
to obtain current-voltage relation curves was significantly
higher, in the 20- to 40-mV voltage range, in DT compared
with control cells (Figure 7A). These results suggest that
increased myocyte contraction in NOS1 transgenic mice is
driven by greater Ca2 entry via L-type Ca2 channels.
After TAC in control mice, the peak Ca2 transient was
decreased significantly together with a prolonged transient
Figure 3. Summary data from M-mode
echocardiography in conscious animals
(n6 to 10 per group) demonstrating dilated
hypertrophy with decreased fractional short-
ening in control (Ctrl)TAC but concentric
hypertrophy with preserved fractional short-
ening in DTTAC hearts. Wall thickness fur-
ther increases in DT mice in response to
TAC. LV end-diastolic (LVEDD) and end-
systolic (LVESD) dimensions and fractional
shortening differed markedly between the
genotypes. *P0.05 vs basal; †P0.05 vs
CtrlTAC; #P0.05 vs DTTAC; $P0.05
vs DT; &P0.05 vs Ctrl.
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decline and a reduction in myocyte shortening (Figure 6B;
P0.05). This was associated with an increase in time to
peak Ca2 transient from 27.72.0 to 33.51.5 ms
(P0.05). There was no significant change in ICaL density
(peak ICa normalized to cell capacitance; Figure 7B), but the
reduction in cell shortening was attributable to a decrease in
SR Ca2 load, as assessed by the maximal caffeine-induced
Ca2 transient (Figure 6B). Remarkably, cardiomyocyte
NOS1 overexpression fully rescued this phenotype after
pressure overload. As such, DT mice subjected to TAC
showed no significant reduction in Ca2 transient amplitude
or SR Ca2 load and no delay in transient decline compared
with DT sham. Time to peak Ca2 transient was also reduced
significantly compared with CtrlTAC (26.41.4 versus
33.51.5 ms, P0.05). In line with this, cell shortening was
fully preserved after TAC. Thus, both SR Ca2 load and Ca2
transient are preserved in NOS1 transgenic mice subjected to
TAC, in marked contrast to CtrlTAC mice.
Immunoblot analysis was used to determine whether
NOS1 overexpression was associated with alterations in
the protein abundance of PLB, SERCA2a, and phosphor-
ylated PLB. Despite no change in SR load and PLB/
SERCA2a ratio in cardiomyocytes from DT mice, phos-
phorylation of PLB was increased significantly at both the
Ser16 and Thr17 sites, which could account for the shorter
Ca2 transient decay (Figure 8A through 8C). After TAC,
there was a significant increase in the PLB/SERCA2a ratio
in control mice due to increased PLB protein expression, a
change that is associated with depressed contractile reserve
in the maladaptive hypertrophied heart. In addition, al-
though PLB phosphorylation at the Ser16 site was signif-
icantly greater in control banded animals, the PLB-Ser16/
PLB ratio was significantly reduced in CtrlTAC mice. In
contrast, the PLB/SERCA2a ratio was unaltered in
DTTAC mice. Furthermore, in response to TAC, PLB
phosphorylation was further increased in DT mice at both
sites compared with CtrlTAC, which resulted in in-
creased PLB-Ser16/PLB and PLB-Thr17/PLB ratios.
Potential Ca2-Dependent Signaling Pathway
Involved in NOS1-Mediated Cardiac Hypertrophy
Because cardiomyocyte NOS1 was found to modulate intra-
cellular Ca2 cycling, we tested whether NOS1-mediated
adaptive cardiac hypertrophy might involve activation of the
Ca2-dependent serine/threonine protein-phosphatase cal-
cineurin. In control mice, TAC increased calcineurin protein
expression and decreased the activity of another prominent
signaling cascade involved in cardiomyocyte hypertrophy,
GSK-3, as shown by an increase in the ratio of phosphor-
ylated to total GSK-3 protein (Data Supplement Figure IIA).
In agreement with our previous morphological and remodel-
ing results, TAC induced a further and significant increase in
both calcineurin expression and phosphorylated GSK-3/
Figure 4. A, Representative semiquantita-
tive reverse-transcription polymerase
chain reaction and average data for atrial
natriuretic peptide (ANP), brain natriuretic
peptide (BNP), -myosin heavy chain
(MHC), skeletal muscle (SK)-actin, and
GAPDH transcripts. B, Red Sirius staining
of hearts sections and average histo-
grams for collagen fraction. n6 per
group. *P0.05 vs basal, †P0.05 vs
CtrlTAC.
3192 Circulation June 24, 2008
 at BIBLIOTHEQUE INTERUNIVERSITAIR on January 14, 2010 circ.ahajournals.orgDownloaded from 
GSK-3 ratio in DT mice (P0.05 for both versus
CtrlTAC). To assess calcineurin activity, we performed
immunoprecipitation experiments between calmodulin and
calcineurin in heart homogenates from the different groups,
as described previously (Data Supplement Figure IIB).22
These experiments showed that there was a greater increase
in calcineurin association with calmodulin after TAC in DT
than in control mice.
Discussion
The major new finding of the present study is that a chronic
increase in cardiomyocyte NOS1 protein expression is asso-
ciated with enhanced cardiac contractility and may be pro-
tective against the development of maladaptive cardiac hy-
pertrophy in the face of increased hemodynamic load. To the
best of our knowledge, this is the first report to demonstrate
the efficacy of selective NOS1 targeting in the setting of
hypertrophy and transition to HF. Mechanistically, the bene-
ficial effects of NOS1 overexpression may be associated with
preserved SR Ca2 cycling, which involves Ca2 load in
particular, through modulation of PLB expression and phos-
phorylation levels.
NOS1 Regulation of Basal Myocyte Contractility
and Calcium Handling
A major new paradigm in NO biology has emerged in the last
few years to suggest that NOS1-derived NO plays an impor-
tant role in the physiological regulation of myocardial con-
traction and Ca2 fluxes. In the present study, we demon-
strated that NOS1-overexpressing mice showed a modest but
significant increase in LV contractile function in vivo com-
pared with control mice. Isolated ventricular myocyte studies
showed that cardiomyocytes overexpressing NOS1 have
greater basal cell shortening, higher Ca2 transients, and
faster relaxation than control littermates.
Several proteins involved in excitation-contraction coupling
are potential targets for NOS1 modulation, and Xu and cowork-
ers10 suggested that NOS1 inhibits the activity of SERCA2a.
Inhibition of SERCA2a would be expected to slow the speed of
relaxation and rate of decay of the [Ca2]i transient in DT
myocytes, because Ca2 reuptake into the SR would occur more
slowly. However, we found that the [Ca2]i transient declined
much more rapidly in DT myocytes than in control myocytes.
Furthermore, SR Ca2 content estimated after rapid caffeine
Figure 5. A, Representative immunostain-
ing of heart sections for capillary density.
Capillaries in LV sections are identified by
anti-Cav-1 antibody (red) and cardio-
myocytes with anti-Cav-3 (green). B, Rep-
resentative immunoblots showing VEGF
and Flk-1 expression in Ctrl and DT LVs
and the response to TAC. *P0.05 vs
basal; †P0.05 vs CtrlTAC; $P0.05 vs
DTTAC.
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application was similar in the 2 groups. One potential explana-
tion would be that NOS1 influences SR Ca2 uptake by
stimulating phosphorylation of PLB. Although the PLB/
SERCA2a ratio was unchanged in DT myocytes, NOS1 over-
expression induced an increase of PLB phosphorylation, which
would stimulate PLB dissociation from SERCA2a and lead to
increased SR Ca2 reuptake. Similarly, it has been demonstrated
recently that both relaxation and the rate of [Ca2]i transient
decay were significantly prolonged in LV myocytes from
NOS1/ mice. Disabling the SR abolished the differences in
both parameters, which suggests that impaired SR Ca2 reuptake
may account for the slower relaxation in NOS1/ mice. In line
with these findings, disruption of NOS1 decreased PLB
phosphorylation.23
A potential alternative target for NOS1 is RyR2, which has
variably been shown to be activated24,25 or inhibited26 by NO.
We found that the time to peak [Ca2]i was reduced signifi-
cantly in myocytes overexpressing NOS1, which could also
explain why SR load was unchanged despite the increase in
Ca2 transient. Although we did not assess whether NOS1
overexpression alters the level of RyR2 protein expression,
coimmunoprecipitation experiments demonstrated that the
level of NOS1 interacting with RyR2 was increased in DT
mice. All these findings are in keeping with the notion that
RyR2 activity could be activated in DT myocytes, as de-
scribed recently.27 NOS1 from the SR may also affect the
L-type Ca2 channel, and consistent with the findings of
increased contractility in myocytes from DT mice, we dem-
onstrated that there was an increased Ca2 current in cardio-
myocytes from DT mice.
The present results are, however, in sharp contrast with
previous studies demonstrating that myocytes from NOS1/
mice had a greater basal cell shortening, associated with a
greater Ca2 influx through L-type Ca2 channels and a larger
SR Ca2 content.12,13 In contrast, others have observed different
effects using the same mice, with no differences in basal
contractility and unchanged L-type Ca2 currents but decreased
cardiomyocyte contractility and calcium transients at higher
pacing rates in isolated cardiomyocytes.11,14 Recently, condi-
tional myocardium-specific NOS1 overexpression was associ-
ated with a decrease in Ca2 current density, [Ca2]i transient
amplitude, SR Ca2 load, and cell shortening.28 Surprisingly,
Figure 6. Overexpression of NOS1 in the car-
diomyocyte rescues cardiac contractile dys-
function in response to pressure overload. A,
Representative line-scan images of fluo-3 fluo-
rescence recorded in 1 control (Ctrl; top) and 1
DT (bottom) myocyte field stimulated at 1 Hz.
B, Bar graphs corresponding to cell shortening,
the amplitude [Ca2 ]i transient (measured as
peak F/F0), [Ca2 ]i transient rate of decay, and
pooled amplitude histogram of [Ca2 ]i tran-
sients induced by 10 mmol/L caffeine (n20
to 35 cells from 4 animals in each group).
*P0.05 vs basal; †P0.05 vs CtrlTAC;
$P0.05 vs DT; &P0.05 vs wild-type.
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those authors28 demonstrated that relaxation time (50%) in the
experiments for myocyte shortening was significantly prolonged
in NOS1-overexpressing mice, a result similar to that obtained
with NOS1/ mice.12 Given that these authors used the same
isoform of NOS1 (the -isoform) to generate their mice as used
in the present study, potential explanations for the opposite
results could be the background of the mice used or the
subcellular localization of the NOS1 transgene. As described
previously, we found that NOS1 was both localized at the SR,
where it physically interacted with RyR2, and at the sarco-
lemma, where it interacted with Cav-3. However, Burkard and
coworkers28 demonstrated interactions of NOS1 with SERCA2a
and the L-type Ca2 channel but were unable to find any
interaction with RyR2.
Figure 7. A, Representative ICaL recording and
plots of average ICaL density vs membrane
potential obtained from cardiomyocytes from
control (Ctrl) and DT mice. B, Bar graphs corre-
sponding to pooled maximal conductance of
ICa,L (n15 to 20 cells from 4 animals in each
group). &P0.05 vs Ctrl.
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NOS1 Overexpression Prevents Cardiac
Dysfunction and Delays HF in Response to
Pressure Overload
During the last few years, emerging data suggest that NOS1
may have important functions in the pathophysiology of
adverse cardiac remodeling. Here, we provide the first evi-
dence that NOS1-overexpressing hearts undergo further hy-
pertrophy, retaining concentric LV remodeling and full con-
tractile function, whereas wild-type mice showed pronounced
chamber dilation and impaired contractility in response to
chronic pressure overload. Consistent with an adaptive role
for myocardial NOS1 overexpression, recent studies found
that NOS1/ mice developed more pronounced LV dilation
after myocardial infarction than control mice.19,20 In contrast,
NOS1 overexpression was recently associated with an in-
crease in cardiac hypertrophy and a failing cardiac phenotype,
because these mice are characterized by increased LV dila-
tion associated with decreased LV ejection fraction.28 How-
ever, the subcellular mechanisms underlying these in vivo
findings were not elucidated.
Sustained cardiac hypertrophy typically progresses to car-
diac dilatation and failure, conditions associated with sub-
stantial morbidity and mortality. Although hypertrophy per se
has been proposed as an early therapeutic target, the blockade
of the growth response is not always beneficial,29–31 and
importantly, inhibition of the growth response is not abso-
lutely required to ameliorate cardiac dysfunction.32,33 Recent
studies have suggested that the critical factor causing cardiac
decompensation after pressure overload may be the failure to
preserve calcium homeostasis and thus myocardial inotropy.
Indeed, defects in SR Ca2 cycling are a highly conserved
signature feature of experimental and human HF, and the
most notable abnormalities are a decrease in Ca2 reentry into
the SR, which is predominantly governed by the activity of
SERCA2a and dysregulated Ca2 release through RyR2. In
both cases, the SR Ca2 level is diminished in failing hearts,
which creates defects in both systolic and diastolic function.
In many forms of human and experimental HF, the down-
regulation of SERCA2a expression level, impairment in the
SERCA2a/PLB ratio, and a decrease in phosphorylated PLB
have been documented. In general, genetic manipulations that
improve Ca2 cycling either by SERCA2a gene therapy or
PLB ablation have been shown to be beneficial in preventing
Figure 8. A, Representative Western blots
showing the response of PLB and SERCA2a
protein expression to TAC in both geno-
types and quantification results for the ratio
PLB/SERCA2a (n6 to 8 per group). Rela-
tive quantification demonstrated a higher
PLB/SERCA2a ratio in CtrlTAC, which
could account for the decrease in calcium
SR load and decrease in cardiomyocyte
contractility. Cardiomyocyte overexpression
of NOS1 normalizes this ratio, which could
account for the preserved function in
DTTAC. B, Western blot analysis and cor-
responding data of PLB phosphorylation
state with site-specific antibodies (Ser16-
and Thr17-site phosphorylation). C, PLB-
Ser16 and PLB-Thr17 phosphorylation
state-specific band intensity normalized to
PLB abundance. &P0.05 vs Ctrl; *P0.05
vs basal; †P0.05 vs CtrlTAC.
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cardiac dysfunction in both transgenic and surgically induced
HF models.34,35 The present results in NOS1 transgenic mice
are consistent with the idea that NOS1 may prevent adverse
remodeling and cardiac deterioration by preserving calcium
cycling and contractile function even though the extent of
hypertrophy is increased in response to pressure overload.
The improvement in contraction appears to be mainly attrib-
utable to higher SR Ca2 loading in NOS1-overexpressing
hearts, as a consequence of a preserved PLB/SERCA2a ratio
and increased phosphorylated PLB level compared with
control mice. A similar result was recently described by
Chohan and coworkers,36 who demonstrated that L-arginine
administration prevented contractile dysfunction in ischemic
reperfused hearts, which was associated with a recovery of
SR function and SR regulation by PLB phosphorylation. This
effect was mainly attributable to myocyte NOS1. In agree-
ment with our findings, SERCA2a overexpression has been
shown to be protective against the pressure-overload–induced
decrease in contractile function, maintaining contractile prop-
erties and Ca2 homeostasis in cardiac myocytes despite
significant hypertrophy.36–38 It is of interest that the hyper-
trophic response was even more pronounced in banded
transgenic animals than in controls.
In conclusion, we demonstrated that conditional transgenic
overexpression of NOS1 may enhance basal cardiac contrac-
tility, as well as play a significant role in maintaining cardiac
contractility and calcium handling during chronic pressure
overload. These findings strongly support the hypothesis that
cardiomyocyte NOS1 might play an important role in cardiac
protection and suggest that NOS1 could represent a new
means of targeting Ca2 regulatory proteins in the setting of
chronic pressure-overload–induced HF.
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CLINICAL PERSPECTIVE
Sustained cardiac hypertrophy typically progress to cardiac dilatation and failure, conditions associated with substantial
morbidity and mortality. The prevention of this deterioration is a major therapeutic goal. Recent studies have suggested that a
critical factor causing cardiac decompensation after pressure overload may be the failure to preserve calcium homeostasis and
thus myocardial inotropy. It is well established that the neuronal (NOS1) isoform of nitric oxide synthase facilitates Ca2 handling
that is central to excitation-contraction coupling. However, the impact of NOS1 on myocardial contractility and Ca2 cycling
remains controversial, and the potential relevance of this mechanism in HF is unknown. Here, we generated a transgenic mouse
with conditional, cardiomyocyte-specific NOS1 overexpression (DT) and studied cardiac remodeling, myocardial Ca2 handling,
and contractility in DT and control mice subjected to transverse aortic constriction (TAC). After TAC, control mice developed
eccentric hypertrophy with evolution toward HF as revealed by a significantly reduced fractional shortening. In contrast, after
TAC, DT mice developed a greater increase in wall thickness and less left ventricular dilatation. Thus, DT mice displayed
concentric hypertrophy with fully preserved fractional shortening. The improvement in contraction appears to be due mainly to
greater sarcoplasmic reticulum Ca2 loading in the NOS1-overexpressing DT hearts. This enhanced Ca2 sarcoplasmic reticulum
loading was a consequence of a preserved ratio of phospholamban to sarcoplasmic reticulum Ca2 ATPase2a and an increased
level of phosphorylated phospholamban. These findings support the hypothesis that cardiomyocyte NOS1 plays an important role
in cardiac protection. They also suggest that NOS1 could represent a new means of targeting Ca2 regulatory proteins in the
setting of chronic pressure-overload HF.
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